Charles E. Cooley

Array ( [id] => 16948153 [patent_doc_number] => 20210206844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Anti-FSTL3 Antibodies And Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/162776 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18350204 [patent_doc_number] => 20230138315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ANTI-ANGPTL3 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/794213 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17794213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18537547 [patent_doc_number] => 20230242645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/792386 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17792386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830842 [patent_doc_number] => 20230399367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/040807 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975547 [patent_doc_number] => 11492395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Polynucleotides for preparing ANGPTL 3/8 complexes [patent_app_type] => utility [patent_app_number] => 17/152174 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10483 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19977204 [patent_doc_number] => 12344665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody [patent_app_type] => utility [patent_app_number] => 17/144385 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 24022 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18322142 [patent_doc_number] => 20230120270 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => NEW POLYPEPTIDE COMPLEX [patent_app_type] => utility [patent_app_number] => 17/791579 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17791579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806176 [patent_doc_number] => 20210128729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => STABLE AQUEOUS ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/142353 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16541 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17142353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822777 [patent_doc_number] => 20210138070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE IMMUNOGLOBULIN CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/135468 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18210559 [patent_doc_number] => 20230056821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => USE OF FUSION PROTEIN IN TREATMENT OF AGE-RELATED MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 17/788181 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939644 [patent_doc_number] => 20240034783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/788226 [patent_app_country] => US [patent_app_date] => 2020-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097833 [patent_doc_number] => 20240117061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => ANTI-BCMA ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/257749 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257749 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915878 [patent_doc_number] => 20210188970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => Leptin Antibodies [patent_app_type] => utility [patent_app_number] => 17/124481 [patent_app_country] => US [patent_app_date] => 2020-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2549 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17124481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095477 [patent_doc_number] => 20210283268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS [patent_app_type] => utility [patent_app_number] => 17/122786 [patent_app_country] => US [patent_app_date] => 2020-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109619 [patent_doc_number] => 20230002499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => METHODS OF CANCER TREATMENT WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/778512 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19473877 [patent_doc_number] => 12103953 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => FGF2 polypeptide with improved temperature stability and protease resistance and use thereof [patent_app_type] => utility [patent_app_number] => 17/779210 [patent_app_country] => US [patent_app_date] => 2020-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 7613 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020670 [patent_doc_number] => 20220372169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => INHIBITION OF THE VE-PTP PHOSPHATASE PROTECTS THE KIDNEY FROM ISCHEMIA-REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 17/774755 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058002 [patent_doc_number] => 20220389088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => ANTI-ANGIOPOIETIN-LIKE 4 (ANGPTL4) ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/771339 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18059370 [patent_doc_number] => 20220390456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => SMALL EXTRACELLULAR VESICLE-ASSOCIATED VEGF AS A PREDICTOR FOR THERAPEUTIC RESPONSES [patent_app_type] => utility [patent_app_number] => 17/769826 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26488 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720135 [patent_doc_number] => 20210087282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => ANTI-NRP1A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 17/030421 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24719 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030421 [rel_patent_id] =>[rel_patent_doc_number] =>)